Plain-English translation of NCT05641753 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 Diabetes research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether evolocumab, a cholesterol-lowering injection, combined with a daily pill can reduce heart disease risk in people with type 1 diabetes. Researchers want to understand how quickly this medication improves the health of blood vessels and whether it helps reduce the day-to-day changes in blood sugar levels that people with type 1 diabetes experience.
People with type 1 diabetes face higher risks of heart disease, even when their blood sugar is well controlled. This study explores whether this medication can help protect the heart and blood vessels in ways we don't yet fully understand.
You likely qualify if…
You likely don't qualify if…
You will receive two injections of the medication over 2 weeks and take a daily oral pill for one month. You'll have blood drawn at visits and can optionally participate in specialized vascular imaging tests—including a non-invasive microscopy test under your tongue and a PET/CT scan—to measure changes in your blood vessel health. The entire commitment is about one month, with the option to participate in additional optional imaging studies to help researchers understand how the treatment affects your heart and blood vessels.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States